Encision Announces Decision to Deregister Common Stock

Medical device company cites high costs and demands of SEC compliance as reasons for deregistration.

Jan. 29, 2026 at 6:23pm

Got story updates? Submit your updates here. ›

Encision Inc., a medical device company that owns patented Active Electrode Monitoring (AEM) Technology, announced that its Board of Directors has approved the filing of a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock. The company cited the high costs and demands on management's time of ongoing SEC and Sarbanes-Oxley compliance as the primary reasons for the decision.

Why it matters

Encision's deregistration will allow the company to save considerable costs associated with public company reporting requirements, but it also means the company's stock will no longer trade on a major exchange and its financial reporting will no longer be subject to SEC oversight.

The details

Encision plans to file the Form 15 on or about January 29, 2026, which will suspend the company's reporting obligations, including the requirement to file annual and quarterly reports. The company intends to continue publishing unaudited quarterly and annual financial results, and its common stock is expected to continue trading over-the-counter, though a maintained trading market is not guaranteed.

  • Encision plans to file the Form 15 deregistration on or about January 29, 2026.
  • The effective date of the deregistration is expected to occur 90 days after the Form 15 filing.

The players

Encision Inc.

A medical device company that owns patented Active Electrode Monitoring (AEM) Technology, which prevents dangerous radiant energy burns in minimally invasive surgery.

Robert Fries

The CEO of Encision Inc.

Got photos? Submit your photos here. ›

What they’re saying

“The Company's decision to deregister was made after careful consideration of the advantages and disadvantages, and considering our size and market capitalization, and the high costs and demands on management's time of our ongoing compliance with SEC and Sarbanes-Oxley reporting requirements. We expect to recognize considerable cost savings associated with this decision.”

— Robert Fries, CEO (Encision Inc.)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Encision's decision to deregister its common stock highlights the challenges that smaller public companies face in meeting the high costs and demands of SEC compliance, even as they seek to maintain a public trading market for their shares.